Effectiveness of Prophylactic Oral and/or Vaginal Probiotic Supplementation in the Prevention of Recurrent Urinary Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Trial

医学 安慰剂 益生菌 内科学 泌尿系统 安慰剂对照研究 抗生素 不利影响 胃肠病学 随机对照试验 临床试验 双盲 微生物学 细菌 病理 生物 替代医学 遗传学
作者
Varsha Gupta,Paola Mastromarino,Ritu Garg
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:78 (5): 1154-1161 被引量:31
标识
DOI:10.1093/cid/ciad766
摘要

Abstract Background Widespread antibiotic resistance has sparked interest in the identification of nonantibiotic strategies, particularly probiotics for the prevention of recurrent urinary tract infections (UTIs). We evaluated the effectiveness of prophylactic probiotic supplementation through oral and intravaginal routes in the prevention of recurrent UTIs. Methods This double-blind, placebo-controlled study enrolled 174 premenopausal women with a history of recurrent UTIs and randomized them to 1 of the 4 treatment groups: placebo (G1, oral placebo + vaginal placebo), oral probiotic (G2, oral lactic acid bacteria and bifidobacteria + vaginal placebo), vaginal probiotic (G3, oral placebo + vaginal lactobacilli), and probiotic combination (oral lactic acid bacteria and bifidobacteria + vaginal lactobacilli), for 4 months. Participants were followed up for symptomatic UTIs for 1 year. The primary end points were the number of symptomatic UTIs at 4 months, the proportion of participants with at least 1 symptomatic UTI, and the time to the first symptomatic UTI. Results The incidence of UTI at 4 months in G1, G2, G3, and G4 was 70.4%, 61.3%, 40.9%, and 31.8%, respectively. The mean number of symptomatic UTI recurrences at 4 months was significantly lower (P < .05) in G3 (1.06) and G4 (1.07) compared with G1 (2.1) and G2 (1.63). Further, the time to first symptomatic UTI (days) was significantly longer (P < .05) in G3 (123.8) and G4 (141.8) compared with G1 (69.3) and G2 (71.9). Probiotic supplementations were well tolerated with no serious adverse events. Conclusions Prophylactic supplementation with either vaginal probiotics or in combination with oral probiotics demonstrated effectiveness in preventing recurrent symptomatic UTI episodes. Clinical Trials Registration Registered at Clinical Trials Registry India (CTRI): CTRI/2014/02/004425 (https://ctri.nic.in).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
DGFR完成签到,获得积分10
刚刚
刚刚
Siqi完成签到,获得积分20
刚刚
天际发布了新的文献求助30
刚刚
自然幻竹完成签到,获得积分10
1秒前
iNk应助霖昭采纳,获得10
1秒前
1秒前
大模型应助张张采纳,获得10
1秒前
usee完成签到,获得积分10
1秒前
嘿嘿完成签到,获得积分10
2秒前
刘尚琴发布了新的文献求助10
2秒前
zcl发布了新的文献求助10
2秒前
dsfsd完成签到,获得积分10
2秒前
bird完成签到,获得积分10
3秒前
勤劳白翠完成签到,获得积分10
4秒前
怡神001完成签到,获得积分10
4秒前
4秒前
yyy完成签到,获得积分10
5秒前
淡定雍完成签到,获得积分10
5秒前
5秒前
5秒前
可靠松鼠发布了新的文献求助10
5秒前
30040完成签到,获得积分10
6秒前
DCC发布了新的文献求助10
6秒前
18621058639完成签到,获得积分10
6秒前
Ankh完成签到,获得积分10
6秒前
6秒前
秦时明月GN完成签到,获得积分10
7秒前
lx完成签到,获得积分10
7秒前
7秒前
秋水黎枫完成签到,获得积分10
7秒前
酷波er应助Riggle G采纳,获得10
8秒前
dfhjsd发布了新的文献求助10
8秒前
黄任行完成签到,获得积分10
8秒前
zyy完成签到,获得积分10
9秒前
9秒前
圆滚滚完成签到,获得积分10
9秒前
小帅完成签到,获得积分10
9秒前
9秒前
PJT-8450发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
Adhesion Science: Principles & Practice 800
Signals, Systems, and Signal Processing 610
IEST-RP-CC018: Cleanroom Cleaning and Sanitization: Operating and Monitoring Procedures 600
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
近红外光谱定性分析原理、技术及应用 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6531080
求助须知:如何正确求助?哪些是违规求助? 8323759
关于积分的说明 17821301
捐赠科研通 5632585
什么是DOI,文献DOI怎么找? 2932583
邀请新用户注册赠送积分活动 1909249
关于科研通互助平台的介绍 1768501